Continuing Education Webinars - On Demand

Myriad Oncology hosts educational content for Nurses and Genetic Counselors throughout the year. These continuing education opportunities have been recorded and can be viewed at your convenience. Listed below are the recorded webinars in the Evolving Strategies in Hereditary Cancer series.

Optional continuing education contact hours can be received if the survey is completed after watching the video.

Please view each individual video for updated instructions on how to receive this continuing education credit.

Evolving strategies in hereditary cancer 2022

This program will evaluate various risk assessment methods and focus on risk reducing therapies for patients with an increased risk of breast cancer.

Learning Objectives

  1. Evaluate current breast cancer risk assessment methods including germline genetics, polygenic risk scores, and risk modeling.
  2. Examine an evidence-based overview of endocrine therapy for breast cancer prevention.
  3. Summarize a practice approach to risk stratification and management for patients with general, moderate, and high risk of developing breast cancer.

This program will discuss risk assessment, treatment and opportunities to increase access for genetic testing for patients at risk or diagnosed with prostate cancer.

Learning Objectives

  1. Define methods in diagnosing and identifying patients with high-risk prostate cancer.
  2. Summarize pathways for prostate cancer treatment planning.
  3. Evaluate barriers to implementation of germline genetic testing for patients with prostate cancer.
  4. Identify opportunities to improve access to germline genetic testing for patients at risk for hereditary prostate cancer

This program will discuss hereditary renal tumor syndromes and highlight criteria for identifying patients at risk for hereditary renal cell carcinoma as well as discuss management for affected patients.

Learning Objectives

  • Identify patients who are at risk for hereditary renal tumor syndromes
  • Define hereditary renal tumor syndromes and related risks
  • Examine management and treatment options for patients with hereditary renal tumor syndromes

This program will highlight challenges in providing equitable care for sexual and gender minority patients and examine strategies to overcome these challenges within a clinical and research construct.

Learning Objectives

  • Review terminology and historical context through which to begin to understand sexual and gender minority (SGM) identities
  • Examine current shortcomings in the healthcare system that perpetuate health disparities in the SGM community
  • Evaluate strategies and guidelines for SGM inclusivity in clinical care and research.

This program will outline current methods to identify patients at risk for hereditary colorectal cancer and discuss potential strategies to improve access for genetic testing and treatment for these patients.

  1. Review current genetic algorithms for identifying patients at risk hereditary CRC and discuss benefits of simplifying these tools.
  2. Examine potential benefits of testing all patients diagnosed with CRC.
  3. Identify challenges in testing all patients with CRC and review current models to identify patients with Lynch Syndrome.
  4. Evaluate genetic testing strategies for all patients with PDAC compared to patients with CRC.

This program will define and examine disparities in digital health literacy and provide solutions to improve education and communication for patients with cancer.

  1. Define health literacy and digital health literacy.
  2. Examine the impact of health literacy on understanding of health information.
  3. Explore the challenges faced in evaluating digital health information.
  4. Discuss tips and resources for communicating about health media reports.

Evolving strategies in hereditary cancer 2021

This webinar will highlight updates in cancer treatment associated with genomic and genetic testing and address challenges and benefits of improving clinical trial enrollment for patients with hereditary cancer.

  1. Summarize tumor BRCA mutations and their implications in treatments beyond ovarian cancer.
  2. Examine barriers to enrolling individuals with inherited mutations into clinical research.
  3. Identify resources available to address challenges in engagement and clinical trial enrollment.

This webinar will examine the American Society of Breast Surgeons (ASBrS) consensus guidelines on genetic testing for all patients with breast cancer and discuss its implications on local and systemic treatment recommendations.

  1. Summarize the American Society of Breast Surgeons’ Consensus Guideline on Genetic Testing for Hereditary Breast Cancer and discuss implications to clinical practice.
  2. Examine recent literature that supports the ASBrS Consensus Guideline on Genetic Testing for Hereditary Breast Cancer in comparison to current NCCN guidelines.

This webinar will outline various disparities in hereditary cancer care and highlight tools, methods, and focused efforts to improve care delivery and reduce barriers in this patient population.

  1. Identify underlying social determinants of health that impact barriers in clinical genetics and hereditary cancer care.
  2. Examine provider-oriented obstacles in accessing genetic services and discuss strategies for empowering patients/families and providers to overcome these barriers.
  3. Evaluate racial disparities in BRCA testing and discuss focused efforts to improve care delivery.

This webinar will summarize highlights from recent 2021 virtual meetings of the Society of Gynecologic Oncology and the National Consortium of Breast Centers, focusing on evolving strategies in hereditary breast and ovarian cancer.

  1. Examine targeted therapies in hereditary ovarian cancer and strategies to manage treatment side effects.
  2. Identify current recommendations for screening, risk reduction and safety/efficacy of exogenous hormones in individuals with a moderate to high risk for breast & ovarian cancer.
  3. Define key components for a comprehensive high-risk clinic.
  4. Summarize the current guidelines for endocrine therapy in patients with germline BRCA mutations and the potential for polygenic risk scores (PRS) as a stratification tool to guide endocrine therapy in patients with hereditary and high-risk familial breast cancer.

This webinar will focus on evolving strategies in hereditary colorectal cancer. Program presentations will highlight novel therapies for risk reduction, additional genes and associated cancer risks as well as discuss the role of polygenic risk scores to identify and stratify colorectal cancer risks.

  1. Evaluate current data and guidelines related to aspirin as chemoprevention in individuals with Lynch and discuss implementation of an aspirin chemoprevention regiment from a clinical perspective.
  2. Summarize findings from an analysis of colon and other cancer risks for monoallelic MUTYH and monoallelic NTHL1 carriers identified by multi-gene panel testing.
  3. Examine current scientific data as it pertains to polygenic risk scores (PRS) and colorectal cancer (CRC)
    • Discuss identification and weighting of single nucleotide variants (SNV)
    • Evaluate additional cancer risk factors including, lifestyle, family history and ancestry challenges
    • Compare PRS vs single gene cancer risks related to colorectal cancer
  • Gender-Inclusive Genetic Counseling- Presented by Danielle McKenna, MS, LCGC and Diane Koeller, MS, MPH, CGC 
    • Evaluate current data related to cancer risk counseling in transgender patients and explore unique considerations
    • Identify opportunities to reduce clinical barriers to care and enhance services for transgender patients
  • Breaking Barriers to Cancer Risk Assessment for Transgender Patients- Presented by Carol Lustig RN MSN ANP-BC  
    • Examine practices of case preparation, case management, appropriate genetic testing, and medical management for transgender patients in the context of hereditary cancer

More webinars coming soon